“Inhibiting DGKi seems to reverse the effects of cystic fibrosis”
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a promising potential drug target for cystic fibrosis. Their work, published online today in Cell, also uncovers a large set of genes not previously linked to the disease, demonstrating how a new screening technique can help identify new drug targets.
Cystic fibrosis is a hereditary disease caused by mutations in a single gene called CFTR. These mutations cause problems in various organs, most notably making the lining of the lungs secrete unusually thick mucus. This leads to recurrent life-threatening lung infections, which make it increasingly hard for patients to breathe. The disease is estimated to affect 1 in every 2500-6000 newborns in Europe.
In patients with cystic fibrosis, the mutations to CFTR render it unable to carry out its normal tasks. Among other things, this means CFTR loses the ability to control a protein called the epithelial sodium channel (ENaC). Released from CFTR’s control, ENaC becomes hyperactive, cells in the lungs absorb too much sodium and – as water follows the sodium – the mucus in patients’ airways becomes thicker and the lining of the lungs becomes dehydrated. The only drug currently available that directly counteracts a cystic fibrosis-related mutation only works on the three percent of patients that carry one specific mutation out of the almost 2000 CFTR mutations scientists have found so far.
Thus, if you were looking for a more efficient way to fight cystic fibrosis, finding a therapy that would act upon ENaC instead of trying to correct that multitude of CFTR mutations would seem like a good option. But unfortunately, the drugs that inhibit ENaC, mostly developed to treat hypertension, don’t transfer well to cystic fibrosis, where their effects don’t last very long. So scientists at EMBL, Regensburg University and University of Lisboa set out to find alternatives.
“In our screen, we attempted to mimic a drug treatment,” says Rainer Pepperkok, whose team at EMBL developed the technique, “we’d knock down a gene and see if ENaC became inhibited.”
Starting with a list of around 7000 genes, the scientists systematically silenced each one, using a combination of genetics and automated microscopy, and analysed how this affected ENaC. They found over 700 genes which, when inhibited, brought down ENaC activity, including a number of genes no-one knew were involved in the process. Among their findings was a gene called DGKi. When they tested chemicals that inhibit DGKi in lung cells from cystic fibrosis patients, the scientists discovered that it appears to be a very promising drug target.
“Inhibiting DGKi seems to reverse the effects of cystic fibrosis, but not block ENaC completely,” says Margarida Amaral from the University of Lisboa, “indeed, inhibiting DGKi reduces ENaC activity enough for cells to go back to normal, but not so much that they cause other problems, like pulmonary oedema.”
The Latest on: Cystic fibrosis
- Plasma microRNA levels in male and female children with cystic fibrosison January 24, 2020 at 2:35 am
Cystic fibrosis (CF) is an autosomal recessive genetic disorder arising from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene 1. CFTR is a crucial chloride ion channel ...
- Relief, excitement as Pharmac funds cystic fibrosis medicineon January 24, 2020 at 1:40 am
Pharmac declined the initial application back in 2014 due to limited evidence of its benefits for cystic fibrosis – a rare disorder that damages the lungs and digestive system. One of the people who ...
- Relief as Pharmac funds cystic fibrosis medicineon January 23, 2020 at 10:51 pm
The father of a young boy with a rare mutation of cystic fibrosis is relieved and excited that Pharmac looks set to finally fund a drug that could mean his son lives decades longer than predicted.
- Cystic Fibrosis (CF) Therapeutics Market Augmented Expansion to Be Registered by 2020-2029on January 22, 2020 at 11:14 pm
Global News of Cystic Fibrosis (CF) Therapeutics Market Study 2020-2029, by Segment (Pancreatic enzyme supplements, Mucolytics, Bronchodilators, CFTR modulators), Playing a Pivotal Role in Expanding ...
- MC Companies Wins 'Rookie Fundraiser Team of the Year' by the Cystic Fibrosis Foundation For National Sponsorship Impacton January 21, 2020 at 5:19 pm
MC Companies San Antonio has won the Cystic Fibrosis Foundation's 'Rookie Fundraiser Team of the Year' award for their presence as a national sponsor and powerful impact at San Antonio Great Strides.
- Cystic Fibrosis Market 2020 – Segmented by Type, Application and Geography – Growth, Trends, and Forecast (2020 – 2027)on January 21, 2020 at 2:39 am
Cystic Fibrosis Market 2020 Global Industry research report gives a comprehensive analysis of the Cystic Fibrosis industry size, growth factors, demand, global share, key players and SWOT analysis ...
- NHS Cystic Fibrosis Campaign Allowed Six Young Sufferers To Receive Wonder Pillson January 21, 2020 at 2:15 am
Boxes of lifesaving wonder pills were received by six young cystic fibrosis sufferers. This will give them another shot at life.
- Cartwheel for a Cure, a Nassau girls gymnastics event, raises funds for the cystic fibrosis causeon January 20, 2020 at 4:17 pm
Kim Rhatigan, the Section VIII gymnastics coordinator and the Bethpage gymnastics coach, said that Cartwheel for a Cure motivates the girls beyond the results in the gym: To raise awareness for cystic ...
- Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failureon January 20, 2020 at 8:10 am
All prices are NET prices. VAT will be added later in the checkout. Leung, D. H. et al. Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life.
- 13-Year-Old Cystic Fibrosis Patient Cries With Family Upon Receiving Wonder Pill Trikaftaon January 20, 2020 at 2:30 am
The 13-year-old cystic fibrosis patient finally received the miracle drug. He wept with joy with his family and thanked the drug company for giving him a chance to breathe.
via Google News and Bing News